Amylyx Pharmaceuticals, Inc.
AMLX
$13.95
-$0.10-0.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.11% | 52.70% | 42.99% | 69.77% | -893.62% |
| Total Depreciation and Amortization | -32.50% | -45.70% | -32.21% | -50.48% | -46.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.64% | -85.95% | -58.30% | -95.65% | -27.02% |
| Change in Net Operating Assets | 100.34% | 81.74% | 214.58% | -5,711.59% | -1,815.03% |
| Cash from Operations | 52.71% | 26.95% | 62.08% | -8,043.97% | -535.45% |
| Capital Expenditure | 99.76% | -226.32% | 80.90% | 83.58% | -10,075.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -70.80% | -86.44% | 179.70% | -5,026.41% | 375.56% |
| Cash from Investing | -54.65% | -86.51% | 179.40% | -5,430.77% | 210.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 154.05% | 441.55% | 53.19% | -32.92% | -57.35% |
| Repurchase of Common Stock | -450.00% | -426.52% | -415.00% | 32.70% | 67.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -289.09% | 239,407.50% | -214.81% | 50,023.66% | -52.17% |
| Foreign Exchange rate Adjustments | 122.48% | -36.02% | 1,658.97% | 279.09% | -321.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -73.46% | 6,934.50% | 98.24% | -5,121.08% | -84.10% |